Doxepin (Silenor)
FDA ApprovedTricyclic Antihistamine | Ultra-Low Dose Sleep Aid
Community Research
Join others researching Doxepin — share findings, ask questions, and learn from real experiences
Doxepin is a tricyclic compound with a remarkably dose-dependent pharmacological profile. At higher doses (75-300 mg), it functions as a traditional tricyclic antidepressant (TCA) with activity across multiple neurotransmitter systems. However, at ultra-low doses (3-6 mg), doxepin acts almost exclusively as a highly selective histamine H1 receptor antagonist, making it one of the most targeted sleep maintenance agents available. This ultra-low dose formulation was approved by the FDA in 2010 under the brand name Silenor specifically for the treatment of insomnia characterized by difficulty with sleep maintenance. The distinction between high-dose and ultra-low dose doxepin is critical: at 3-6 mg, the drug avoids the anticholinergic, noradrenergic, and serotonergic side effects that characterize tricyclic antidepressants, resulting in a remarkably clean side effect profile. For biohackers and those seeking a non-habit-forming sleep aid, ultra-low dose doxepin offers a compelling option -- it does not produce dependence, does not cause rebound insomnia upon discontinuation, and maintains efficacy with long-term use. Unlike benzodiazepines and Z-drugs, it carries no abuse potential and is not a scheduled substance.
At ultra-low doses (3-6 mg), doxepin's mechanism of action is dominated by potent and selective antagonism of the histamine H1 receptor. Doxepin has one of the highest affinities for the H1 receptor of any known compound (Ki approximately 0.17 nM), which means that even at very low plasma concentrations, it effectively blocks histaminergic wakefulness signaling. The histamine system is a key component of the ascending arousal pathway -- histaminergic neurons in the tuberomammillary nucleus of the hypothalamus fire during wakefulness and become quiescent during sleep. By blocking H1 receptors, ultra-low dose doxepin reduces this wake-promoting signal, particularly during the latter half of the night when endogenous histamine levels naturally begin to rise, which is why it is especially effective for sleep maintenance insomnia. At these low doses, doxepin has negligible affinity for muscarinic, adrenergic, and serotonergic receptors, which explains the absence of anticholinergic side effects (dry mouth, constipation, urinary retention) and cardiovascular effects that plague higher-dose TCA use. At antidepressant doses (75-300 mg), doxepin additionally inhibits reuptake of serotonin and norepinephrine and blocks muscarinic, alpha-1 adrenergic, and 5-HT2 receptors, producing a much broader and less selective pharmacological profile.
Molecular Data
Research Indications
Silenor (doxepin 3 mg and 6 mg) is FDA-approved for the treatment of insomnia characterized by difficulty with sleep maintenance. Clinical trials demonstrated that ultra-low dose doxepin significantly improved sleep maintenance (wake after sleep onset) and total sleep time without next-morning residual effects at the 3 mg dose, and with minimal residual effects at 6 mg.
At higher doses (75-300 mg), doxepin is FDA-approved for the treatment of depression and anxiety associated with depression. However, this use is largely historical, as newer antidepressants with more favorable side effect profiles have supplanted TCAs for most patients. The antidepressant dosing range is entirely separate from the ultra-low dose sleep application.
Clinical data supports the efficacy and safety of ultra-low dose doxepin for long-term insomnia management. Unlike many hypnotics, doxepin at 3-6 mg maintains its efficacy over months of continuous use without dose escalation, making it suitable for chronic insomnia in patients who need a sustainable, long-term solution.
Ultra-low dose doxepin is one of the few sleep medications with specific safety and efficacy data in elderly patients. The 3 mg dose is recommended for older adults and has been shown to improve sleep maintenance without the falls, cognitive impairment, and next-day sedation risks associated with benzodiazepines and Z-drugs in this population.
Dosing Protocols
Ultra-low dose doxepin is available as Silenor tablets (3 mg, 6 mg). Higher-dose formulations for depression are available as generic capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg) and an oral concentrate. For sleep, only the 3 mg and 6 mg tablets are appropriate. The drug should be taken within 30 minutes of bedtime and not within 3 hours of a meal, as food can delay absorption and increase the risk of next-day drowsiness.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Sleep Maintenance - Starting Dose | 3 mg | Once at bedtime | Oral tablet |
| Sleep Maintenance - Standard Dose | 6 mg | Once at bedtime | Oral tablet |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Morning drowsiness or grogginess (more common at the 6 mg dose; uncommon at 3 mg)
- Dry mouth (mild at ultra-low doses, much less than at antidepressant doses)
- Nausea
- Upper respiratory tract infection (observed in clinical trials at rates similar to placebo)
Stop Signs - Discontinue if:
- Signs of allergic reaction: rash, hives, swelling of the face, lips, or throat, difficulty breathing
- Signs of serotonin syndrome: agitation, confusion, rapid heart rate, elevated body temperature, muscle rigidity
- Severe or persistent morning drowsiness that impairs daily function
- Irregular heartbeat, chest pain, or palpitations
- Worsening depression or emergence of suicidal thoughts
Contraindications
- Known hypersensitivity to doxepin or other dibenzoxepines
- Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
- Untreated narrow-angle glaucoma
- Severe urinary retention
- Severe hepatic impairment (doxepin is extensively hepatically metabolized)
Frequently Asked Questions
What's the difference between Silenor (3-6 mg) and regular doxepin (75-300 mg)?
They are fundamentally different drugs at different doses. Ultra-low dose doxepin (Silenor at 3-6 mg) acts almost exclusively as a highly selective H1 antihistamine, avoiding the anticholinergic and monoamine-related side effects of higher doses. Regular doxepin at 75-300 mg is a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake and blocks muscarinic receptors, causing dry mouth, constipation, and other side effects. At 3-6 mg, doxepin is one of the safest and cleanest sleep agents available with no dependence potential. At 75-300 mg, it has the side effect profile of a traditional TCA. Do not confuse the two -- only Silenor (3-6 mg) is appropriate for sleep, and prescription of higher-dose formulations for insomnia is poor practice.
Why is ultra-low dose doxepin better than melatonin or other sleep supplements?
Doxepin at 3-6 mg is an FDA-approved pharmaceutical with robust clinical evidence for improving sleep maintenance (staying asleep through the night), whereas melatonin is a dietary supplement with less consistent evidence and is better for sleep onset than sleep maintenance. Doxepin's mechanism (selective H1 blockade) directly targets the histamine-driven wakefulness system, making it particularly effective for early-morning awakenings and the sleep fragmentation that plagues many insomniacs. Additionally, doxepin maintains efficacy long-term without tolerance development, does not cause dependence, does not have rebound insomnia upon stopping, and has one of the best side effect profiles of any sleep medication. Melatonin works differently and is less predictable for most users.
Can I take doxepin long-term without needing higher doses?
Yes, this is one of doxepin's major advantages. Unlike benzodiazepines, Z-drugs (Ambien, Lunesta), or even some other sedating compounds, doxepin at 3-6 mg does not develop tolerance with long-term use. Clinical studies have documented sustained efficacy over 12+ weeks of continuous use without dose escalation needed. Many patients use ultra-low dose doxepin for years at a stable 3-6 mg dose with consistent sleep improvements. When discontinued, there is no rebound insomnia (unlike benzodiazepines and Z-drugs), making it a sustainable long-term solution for chronic insomnia.
Will doxepin make me groggy the next morning?
At the 3 mg dose, morning grogginess is uncommon. At the 6 mg dose, some mild morning drowsiness may occur during the first few days of use, but most users find it resolves quickly. The key is to take doxepin within 30 minutes of bedtime and on an empty stomach (do not take within 3 hours of a meal). Food delays absorption and increases the risk of next-morning residual sedation. With proper timing, the long half-life (~15 hours) of doxepin means it provides sleep maintenance throughout the night while allowing adequate clearance for daytime alertness by morning. Elderly patients should start at 3 mg to minimize next-day effects.
References
- Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary InsomniaRoth, T., Rogowski, R., Hull, S., et al.Sleep (2007)
Randomized, double-blind, placebo-controlled trial demonstrating that doxepin at 1 mg, 3 mg, and 6 mg significantly improved sleep maintenance (wake after sleep onset) and total sleep time in adults with primary insomnia. The 3 mg and 6 mg doses showed the most robust improvements, with minimal next-day residual effects.
- Low-Dose Doxepin for Insomnia: A Review of the EvidenceKrystal, A.D., Lankford, A., Durrence, H.H., et al.Journal of Clinical Sleep Medicine (2011)
Comprehensive review of clinical evidence supporting ultra-low dose doxepin for insomnia. Confirmed that doxepin at 3-6 mg selectively targets H1 receptors without significant activity at muscarinic, adrenergic, or serotonergic receptors, resulting in effective sleep maintenance with a side effect profile comparable to placebo.
- Doxepin 6 mg and Its Effect on Sleep in Elderly Patients with Primary InsomniaScharf, M., Rogowski, R., Hull, S., et al.American Journal of Geriatric Psychiatry (2008)
Study in elderly patients (65+) with primary insomnia demonstrating that doxepin 1 mg and 3 mg significantly improved sleep maintenance. The low doses were well-tolerated in the elderly population with no significant next-day residual sedation, cognitive impairment, or falls risk, making it one of the safer insomnia treatments for older adults.
- Long-Term Efficacy and Safety of Doxepin 3 mg and 6 mg in Elderly Subjects with Primary InsomniaKrystal, A.D., Durrence, H.H., Scharf, M., et al.Sleep (2010)
12-week study demonstrating sustained efficacy of ultra-low dose doxepin for insomnia in elderly subjects without evidence of tolerance, rebound insomnia, or withdrawal effects upon discontinuation. Confirmed the long-term safety and viability of doxepin as a non-habit-forming sleep maintenance aid.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.